Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma
BackgroundLymphangiogenesis (LYM) has an important role in tumor progression and is strongly associated with tumor metastasis. However, the clinical application of LYM has not progressed as expected. The potential value of LYM needs to be further developed in lung adenocarcinoma (LUAD) patients.Meth...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354339/full |
| _version_ | 1797224202335420416 |
|---|---|
| author | Weichang Yang Weichang Yang Zhijian Wu Shanshan Cai Zhouhua Li Wenjun Wang Juan Wu Hongdan Luo Xiaoqun Ye |
| author_facet | Weichang Yang Weichang Yang Zhijian Wu Shanshan Cai Zhouhua Li Wenjun Wang Juan Wu Hongdan Luo Xiaoqun Ye |
| author_sort | Weichang Yang |
| collection | DOAJ |
| description | BackgroundLymphangiogenesis (LYM) has an important role in tumor progression and is strongly associated with tumor metastasis. However, the clinical application of LYM has not progressed as expected. The potential value of LYM needs to be further developed in lung adenocarcinoma (LUAD) patients.MethodsThe Sequencing data and clinical characteristics of LUAD patients were downloaded from The Cancer Genome Atlas and GEO databases. Multiple machine learning algorithms were used to screen feature genes and develop the LYM index. Immune cell infiltration, immune checkpoint expression, Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and drug sensitivity analysis were used to explore the correlation of LYM index with immune profile and anti-tumor therapy.ResultsWe screened four lymphangiogenic feature genes (PECAM1, TIMP1, CXCL5 and PDGFB) to construct LYM index based on multiple machine learning algorithms. We divided LUAD patients into the high LYM index group and the low LYM index group based on the median LYM index. LYM index is a risk factor for the prognosis of LUAD patients. In addition, there was a significant difference in immune profile between high LYM index and low LYM index groups. LUAD patients in the low LYM index group seemed to benefit more from immunotherapy based on the results of TIDE algorithm.ConclusionOverall, we confirmed that the LYM index is a prognostic risk factor and a valuable predictor of immunotherapy response in LUAD patients, which provides new evidence for the potential application of LYM. |
| first_indexed | 2024-04-24T13:49:22Z |
| format | Article |
| id | doaj.art-72639bee83d3495b874173061eb95394 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T13:49:22Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-72639bee83d3495b874173061eb953942024-04-04T05:06:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.13543391354339Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinomaWeichang Yang0Weichang Yang1Zhijian Wu2Shanshan Cai3Zhouhua Li4Wenjun Wang5Juan Wu6Hongdan Luo7Xiaoqun Ye8Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaJiangxi Key Laboratory of Molecular Medicine, Nanchang, Jiangxi, ChinaDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaBackgroundLymphangiogenesis (LYM) has an important role in tumor progression and is strongly associated with tumor metastasis. However, the clinical application of LYM has not progressed as expected. The potential value of LYM needs to be further developed in lung adenocarcinoma (LUAD) patients.MethodsThe Sequencing data and clinical characteristics of LUAD patients were downloaded from The Cancer Genome Atlas and GEO databases. Multiple machine learning algorithms were used to screen feature genes and develop the LYM index. Immune cell infiltration, immune checkpoint expression, Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and drug sensitivity analysis were used to explore the correlation of LYM index with immune profile and anti-tumor therapy.ResultsWe screened four lymphangiogenic feature genes (PECAM1, TIMP1, CXCL5 and PDGFB) to construct LYM index based on multiple machine learning algorithms. We divided LUAD patients into the high LYM index group and the low LYM index group based on the median LYM index. LYM index is a risk factor for the prognosis of LUAD patients. In addition, there was a significant difference in immune profile between high LYM index and low LYM index groups. LUAD patients in the low LYM index group seemed to benefit more from immunotherapy based on the results of TIDE algorithm.ConclusionOverall, we confirmed that the LYM index is a prognostic risk factor and a valuable predictor of immunotherapy response in LUAD patients, which provides new evidence for the potential application of LYM.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354339/fulllymphangiogenesislung adenocarcinomaimmune cell infiltrationprognosisimmunotherapy |
| spellingShingle | Weichang Yang Weichang Yang Zhijian Wu Shanshan Cai Zhouhua Li Wenjun Wang Juan Wu Hongdan Luo Xiaoqun Ye Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma Frontiers in Immunology lymphangiogenesis lung adenocarcinoma immune cell infiltration prognosis immunotherapy |
| title | Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| title_full | Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| title_fullStr | Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| title_full_unstemmed | Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| title_short | Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| title_sort | tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma |
| topic | lymphangiogenesis lung adenocarcinoma immune cell infiltration prognosis immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354339/full |
| work_keys_str_mv | AT weichangyang tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT weichangyang tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT zhijianwu tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT shanshancai tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT zhouhuali tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT wenjunwang tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT juanwu tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT hongdanluo tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma AT xiaoqunye tumorlymphangiogenesisindexrevealstheimmunelandscapeandimmunotherapyresponseinlungadenocarcinoma |